Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is a high-growth company with a differentiated approach in the medical aesthetics market, targeting millennials and bypassing third-party payer dynamics. With Jeuveau, they hold a strong 14% market share in the US and expanding presence overseas. Their recent launch of new products and strong balance sheet position them well for future growth. However, potential risks include competition, pricing pressure, and regulatory delays.

Bears say

Evolus is facing multiple headwinds, including a highly competitive market for injectable aesthetic products, with Botox being the dominant player. The company's heavy reliance on Evolysse, which has yet to gain significant market traction, also adds to its vulnerability. In addition, Evolus' financials show a substantial amount of debt and reliance on equity offerings, indicating a precarious financial position.

Evolus (EOLS) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Evolus (EOLS) has a Strong Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.